News - Biotechnology
ASX biotech Alterity edges closer to first treatment for rare neurodegenerative disease
An ASX-listed biotech is pushing the boundaries of neurodegenerative research with the development of an AI-powered neuroimaging tool designed to […]
MoreNews - Biotechnology
Australia’s IP trends reveal post-pandemic innovation shift
Australia’s life sciences sector continues to evolve amidst a dynamic landscape of intellectual property (IP) rights, particularly patents, which are […]
MoreNews - Biotechnology
CSL reshapes R&D while bracing for U.S. tariffs
Australia’s largest biotech company CSL is streamlining its R&D operations to enhance efficiency amidst a rapidly evolving global landscape. The […]
MoreNews - Biotechnology
National push to tackle cardiovascular and diabetes burden backs Aussie start-ups
Fourteen biotech and medtech innovators will share in a $12 million funding injection aimed at fast-tracking life-changing solutions for people […]
MoreNews - Biotechnology
Aussie-invented smart capsule wins regulatory nod
An ingestible gas-sensing capsule originally developed at RMIT University has received regulatory clearance from the U.S. Food and Drug Administration […]
MoreNews - Biotechnology
QBiotics reports promising data in rare cancer trial
On Rare Cancers Awareness Day (26 June), Australian biotech QBiotics Group unveiled the final efficacy and safety results from stage […]
MoreNews - Biotechnology
AusBiotech champions Australia’s momentum in the global life sciences race
AusBiotech has wrapped up a week packed with bilateral and multilateral engagements at the BIO International Convention 2025 in Boston. […]
MoreNews - Biotechnology
Local biotech earns green light to manufacture next-gen cell therapies
A Melbourne-based biotech company has secured a stem cell manufacturing licence from the Therapeutic Goods Administration (TGA), a move that […]
MoreNews - Biotechnology
NRF backs local ophthalmic biotech
A Melbourne-based biotechnology company has landed a game-changing investment to push forward its novel glaucoma implant to address the long-standing […]
MoreNews - Biotechnology
Purpose, policy and the future of clinical trials: Noxopharm CEO on what’s next for Australian biotech
As the world marks Clinical Trials Day (20 May), Dr Gisela Mautner, CEO of ASX-listed biotech Noxopharm, brings a bold […]
MoreRecent Posts in Pharma, MedTech & Biotech
CEO roundtable to tackle private health deadlock
September 1, 2025
in News - MedTech & Diagnostics
Rare cancer patients pay the price of policy paralysis: New report
September 1, 2025
in News - Pharmaceuticals
PBS listing delivers first IL-4/IL-13 inhibitor for young children with severe asthma
September 1, 2025
in News - Pharmaceuticals
Pfizer’s pneumococcal vaccine funded after a blurry 1000+ days
September 1, 2025
in News - Pharmaceuticals
Second only to breast cancer: Women face rising blood cancer rates as funding lags decades behind
September 1, 2025
in News - Pharmaceuticals
Opposition and Independents turn up the heat on HTA Review delays
August 29, 2025
in News - Pharmaceuticals
Boehringer Ingelheim tops pharma reputation rankings in ANZ, with Sanofi and Pfizer in close pursuit
August 29, 2025
in News - Pharmaceuticals
Ophthalmologists look to technology to bridge gaps in vision impairment: Roche report
August 29, 2025
in News - Pharmaceuticals
Follow Us
Partner with us
News - MedTech & Diagnostics
CEO roundtable to tackle private health deadlock
Australia’s largest medical indemnity provider representing 95,000 doctors, Avant Mutual, is stepping into the private healthcare policy battlefield, convening 36 […]
MoreNews - Pharmaceuticals
Rare cancer patients pay the price of policy paralysis: New report
Rare Cancers Australia (RCA) is set to release a new report exposing the staggering disparities faced by Australians with rare […]
MoreNews - Pharmaceuticals
PBS listing delivers first IL-4/IL-13 inhibitor for young children with severe asthma
From 1 September, children aged 6–11 years with severe and uncontrolled asthma driven by type 2 inflammation will have access […]
MoreNews - Pharmaceuticals
Pfizer’s pneumococcal vaccine funded after a blurry 1000+ days
From 1 September, Pfizer’s Prevenar 20 (PCV20) officially enters the National Immunisation Program (NIP), becoming the only funded 20-valent pneumococcal […]
More